Komori
PHC Holdings (6523) · RiskMitigated

Revenue decline due to a shrinking BGM market and the end of the U.S. sales partnership

First written in FY2022-Q3. 8 of 14 entries say "Worsened", first in FY2023-Q1. Latest entry: 2026-08-06.

14entries
5years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseWorsenedFY2023-Q1 – FY2024RestatedFY2025-H1MitigatedFY2026-H1 – 2026-08-062022: 320222023: 320232024: 320242025: 220252026: 32026
Same theme, other companies
Revenue decline due to BGM market contraction and the end of the US sales collaborationA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. 2026-08-06MitigatedFinancial results

    「Despite the continued contraction of developed-country markets and the shift to lower-priced channels, revenue increased due to higher sales volumes in the United States and strong sales in Europe, particularly in Germany, Italy, and Greece.」

    Although the contraction of developed-country markets and the shift to lower-priced channels continued, strong sales in the United States and Europe resulted in higher revenue for Diabetes Management.
  2. FY2026MitigatedAnnual report

    「The BGM business posted higher revenue despite the continued contraction of markets in developed countries and the shift to lower-priced channels, as the impact of the end of the US sales collaboration had almost disappeared and initiatives undertaken during the period to increase unit prices and sales volumes proved effective. Sales in Europe also remained strong.」

    The BGM business posted higher revenue as the impact of the end of the US sales collaboration had almost disappeared, while initiatives to increase unit prices and sales volumes and strong European sales offset the continued contraction of developed-country markets and the shift to lower-priced channels.
  3. 2026-05-13MitigatedFinancial results

    「In the United States, the impact of the end of the sales collaboration had almost disappeared, and sales increased as pricing initiatives and measures to increase sales volumes implemented during the fiscal year proved effective. Sales were also solid in Europe.」

    Although the contraction of developed-country markets and the shift to lower-priced channels continued, the impact of the end of the U.S. sales collaboration had almost disappeared, and the BGM business increased revenue through pricing initiatives and higher sales volumes.
  4. FY2026-H1MitigatedAnnual report

    「The BGM business performed well despite the continued contraction of markets in developed countries and the shift to lower-priced channels, as the impact of the end of the US sales collaboration diminished, initiatives to increase unit prices and sales volumes proved effective, and sales in Europe remained strong.」

    The BGM business performed well as the impact of the end of the US sales collaboration diminished, while initiatives to increase unit prices and sales volumes and strong European sales offset the continued contraction of developed-country markets and the shift to lower-priced channels.
  5. FY2025WorsenedAnnual report

    「The BGM market is expected to contract at an annual average rate of 4–5% over the next 3 years, due to factors including revisions to insurance reimbursement in developed markets and the growing adoption of continuous glucose monitoring (CGM) devices.」

    The company quantitatively indicated that the developed-market BGM market is expected to contract at an annual average rate of 4–5% over the next 3 years. The BGM business also posted lower revenue, with the effects of market contraction, the shift to lower-priced channels and the end of the US sales partnership continuing.
  6. FY2025-H1RestatedAnnual report

    「In the blood glucose monitoring (BGM) business, revenue benefited from favorable foreign exchange movements and increased in emerging markets, where market growth is continuing, but declined slightly as market contraction in developed markets such as Europe and the US, the shift to lower-priced channels and the impact of the end of the sales partnership in the US continued. Although the company's market share in Europe increased, this was insufficient to offset the effects of the continuing market contraction.」

    While revenue increased in emerging markets and market share expanded in Europe, the contraction of developed markets, the shift to lower-priced channels and the impact of the end of the US sales partnership have continued.
  7. FY2024WorsenedAnnual report

    「Revenue in the BGM business increased in emerging markets, where market growth is continuing, and benefited from foreign exchange movements, but declined as market contraction continued mainly in Europe and the impact of the end of the sales partnership in the US persisted.」

    Despite revenue growth in emerging markets and favorable foreign exchange effects, diabetes management revenue declined by 2.5% as the contraction of the European market and the impact of the end of the US sales partnership continued over the full fiscal year.
  8. FY2024-Q3WorsenedAnnual report

    「Revenue in the BGM business increased in emerging markets, where market growth is continuing, but declined mainly due to continued market contraction in Europe and the impact of the end of the sales partnership in the US.」

    Although revenue increased in emerging markets, the BGM business posted a 4.0% year-on-year decline in revenue as the European market continued to contract and the impact of the end of the US sales partnership continued.
  9. FY2024-Q2WorsenedAnnual report

    「Revenue in the BGM business increased in emerging markets, where the market is growing, but declined due to continued market contraction in the US, Europe, Japan and other markets and the impact of the end of the sales partnership in the US.」

    While revenue increased in emerging markets, markets in the US, Europe, Japan and elsewhere continued to contract, and the impact of the end of the US sales partnership also continued, resulting in lower revenue in the BGM business.
  10. FY2024-Q1WorsenedAnnual report

    「Revenue in the BGM business declined year on year. The main factors were revenue growth in emerging markets and market share gains through the self-pay customer channel in the US, offset by continued overall market contraction and the impact of the end of the sales partnership in the US, as well as revenue declines in Germany, Italy and Poland amid contracting markets.」

    Despite progress in emerging markets and the US self-pay customer channel, the BGM business posted lower revenue as the contraction of developed-market economies and the impact of the end of the US sales partnership continued.
  11. FY2023-Q3WorsenedAnnual report

    「Revenue increased in emerging markets, including the Asia-Pacific region, while in the US, revenue declined because the impact of the end of the sales partnership continued despite market share gains through the self-pay customer channel. Revenue also declined in the UK and Italy as their markets continued to contract.」

    In the US, the impact of the end of the sales partnership continued despite market share gains through the self-pay customer channel, while revenue continued to decline in the UK and Italy as their markets contracted.
  12. FY2023-Q2WorsenedAnnual report

    「While sales increased in China and other Asia-Pacific markets, revenue declined in the US despite gaining market share through the self-pay customer channel, as the impact of the end of the sales partnership continued amid overall market contraction. Revenue also declined in the UK and Italy as those markets continued to contract.」

    In the US, the impact of the end of the sales partnership continued despite market share gains through the self-pay customer channel, while revenue declined in the UK and Italy as their markets continued to contract.
  13. FY2023-Q1WorsenedAnnual report

    「Sales increased in Germany, China and India, but in the US, sales declined despite efforts to expand the self-pay customer channel, which is not covered by insurance, as the market continued to contract. Sales also declined in Canada and Italy despite market share gains as those markets continued to contract.」

    Markets in the US, Canada and Italy continued to contract, and sales declined despite efforts to expand sales channels and market share.
  14. FY2022-Q3First statedAnnual report

    「In the US, revenue declined significantly due to the market's contraction and the end of the sales partnership. Revenue also declined in Germany as the market contracted.」

    In the BGM business, the contraction of the market and the end of the sales partnership materialized as lower revenue in the US and Germany.
Moved together

"Earnings recovery and improved profitability" moved the same way as this thread, in the same document, in 11 of its 14 moves.

1175555★123456
  1. ★This thread
  2. 1Earnings recovery and improved profitability11×
  3. 2Business Impact of COVID-19 and Recovery7×
  4. 3Improvement in the Ratio of Equity Attributable to Owners of the Parent5×
  5. 4Supply Chain Constraints and Rising Raw Material and Logistics Costs5×
  6. 5Fair Value Changes Related to Senseonics5×
  7. 6Capturing demand related to COVID-195×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PHC Holdings yet. It last moved in the Financial results of 2026-08-06: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Revenue decline due to a shrinking BGM market and the end of the U.S. sales partnership | PHC Holdings Corporation (6523) | Komori